User:Kandyskim/sandbox

EE should be avoided in women with a history of or known susceptibility to arterial or venous thrombosis (blood clots), due to an increased risk of venous thromboembolism (VTE), myocardial infarction and ischemic stroke. This includes women with history of DVT/PE not receiving anticoagulant therapy, acute DVT/PE, prolonged immobilization due to major surgery, advanced diabetes mellitus with vascular disease, migraine with aura, hypertension ≥160/100 or vascular disease, current and history of ischemic heart disease, multiple risk factors for atherosclerotic cardiovascular disease (e.g. older age, smoking, diabetes, hypertension, low HDL, high LDL, or high triglyceride levels), age ≥35 and smoking ≥15 cigarettes/day, history of cerebrovascular accident, systemic lupus erythematosus with positive (or unknown) antiphospholipid antibodies, and complicated valvular heart disease. EE should also be avoided in breastfeeding women <21 days postpartum due to an increased risk of VTE. Discussions about EE use in breastfeeding women ≥21 days postpartum should include information about risks, benefits, and alternatives.

COCs containing EE should also be avoided in women with current breast cancer due to a possible worsening of prognosis. Kandyskim (talk) 00:05, 30 October 2017 (UTC)

Contraindications
EE should be avoided in women with a history of or known susceptibility to arterial or venous thrombosis (blood clots), due to an increased risk of venous thromboembolism (VTE), myocardial infarction and ischemic stroke. This includes women with: EE should also be avoided in breastfeeding women <21 days postpartum due to an increased risk of VTE. EE use in breastfeeding women ≥21 days postpartum should be discussed with a provider and include information on the advantages, disadvantages, and alternatives to using EE.
 * History of DVT/PE not receiving anticoagulants
 * Acute DVT/PE
 * Prolonged immobilization due to major surgery
 * Advanced diabetes mellitus with vascular disease
 * Migraine with aura
 * Hypertension ≥160/100
 * Vascular disease
 * Current and history of ischemic heart disease
 * Multiple risk factors for atherosclerotic cardiovascular disease (e.g. older age, smoking, diabetes, hypertension, low HDL, high LDL, or high triglyceride levels)
 * Age ≥35 and smoking ≥15 cigarettes/day
 * History of cerebrovascular accident
 * Systemic lupus erythematosus with positive (or unknown) antiphospholipid antibodies
 * Complicated valvular heart disease

Due to risk of cholestatic hepatotoxicity, it is widely considered that COCs containing EE should be avoided in women with a history of cholestasis of pregnancy, hepatic tumors, active hepatitis, and familial defects in biliary excretion. COCs containing EE should also be avoided in women with current breast cancer due to a possible worsening of prognosis. Kandyskim (talk) 17:49, 9 November 2017 (UTC)